In conclusion, the findings demonstrate the role of KAT6A LLPS in fostering PARPi resistance and suggest that repressing KAT6A LLPS can be a potential therapeutic strategy for PARPi‐resistant ovarian cancer. This evidence concerns the gene KAT6A and ovarian carcinoma.